Propanc Biopharma (NASDAQ:PPCB) Shares Scheduled to Reverse Split on Monday, October 26th

Propanc Biopharma Inc (NASDAQ:PPCB) shares are going to reverse split on Monday, October 26th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Propanc Biopharma Stock Performance

Shares of NASDAQ PPCB traded down $0.05 during trading on Thursday, reaching $0.27. The company had a trading volume of 206,529 shares, compared to its average volume of 348,886. Propanc Biopharma has a twelve month low of $0.27 and a twelve month high of $38.25. The stock has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $1.48.

Propanc Biopharma (NASDAQ:PPCB) last issued its quarterly earnings data on Friday, September 25th. The company reported ($1.77) earnings per share (EPS) for the quarter.

Propanc Biopharma announced that its board has approved a share repurchase program on Thursday, July 2nd that authorizes the company to repurchase $500,000.00 in outstanding shares. This buyback authorization authorizes the company to buy up to 15.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

About Propanc Biopharma

Propanc Biopharma, Inc is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on proenzyme-based cancer therapies designed to target the tumor microenvironment and address cancer recurrence and metastasis.

Propanc’s lead investigational product is PRP, a formulation of two digestive proenzymes, trypsinogen and chymotrypsinogen. The company is developing PRP for potential use against advanced and recurrent cancers, including pancreatic, ovarian and colorectal cancers.